يعرض 1 - 7 نتائج من 7 نتيجة بحث عن '"Cèl·lules T - Ús terapèutic"', وقت الاستعلام: 0.92s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Iacoboni G, Barba P, Abrisqueta P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Iraola‐Truchuelo J Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. O’Reilly M Department of Hematology, University College London Hospitals, London, UK. Navarro V Oncology Data Science (ODySey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Menne T Department of Hematology, Freeman Hospital, Newcastle, UK. Kwon M Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: HemaSphere;8(5); https://doi.org/10.1002/hem3.62Test; Iacoboni G, Iraola-Truchuelo J, O’Reilly M, Navarro V, Menne T, Kwon M, et al. Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy. HemaSphere. 2024 May 21;8(5):e62.; https://hdl.handle.net/11351/11604Test; 001228138800001

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Rejeski K Department of Medicine III – Hematology/Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich and Berlin Sites, and German Cancer Research Center, Heidelberg, Germany. Adult BMT and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY. Wang Y, Bansal R Division of Hematology, Mayo Clinic, Rochester, MN. Hansen DK Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL. Iacoboni G, Barba P Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Bachy E Department of Hematology, Lyon Sud Hospital, INSERM 1052, Pierre-Bénite, France, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Blood Advances;8(8); https://doi.org/10.1182/bloodadvances.2023011767Test; Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, et al. Applying the EHA/EBMT Grading for ICAHT after CAR-T: Comparative Incidence and Association with Infections and Mortality. Blood Adv. 2024 Apr 23;8(8):1857–1868.; https://hdl.handle.net/11351/11330Test

  3. 3
    دورية أكاديمية

    المؤلفون: Abrisqueta, Pau

    المساهمون: Institut Català de la Salut, Abrisqueta P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    مصطلحات موضوعية: Cèl·lules B - Tumors - Tractament, Limfomes - Tractament, Anticossos monoclonals - Ús terapèutic, Cèl·lules T - Ús terapèutic, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Other subheadings::Other subheadings::Other subheadings::/drug therapy, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Immunologic Techniques::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Bispecific, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas inmunológicas::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos biespecíficos

    وصف الملف: application/pdf

    العلاقة: Journal of Clinical Medicine;13(7); https://doi.org/10.3390/jcm13071929Test; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F01204; info:eu-repo/grantAgreement/ES/PE2017-2020/PI17%2F00943; Abrisqueta P. New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes? J Clin Med. 2024 Mar 27;13(7):1929.; https://hdl.handle.net/11351/11348Test; 001200883400001

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, León-Román J, Bermejo S, Bolufer M, Bestard O, Soler MJ Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CSUR National Unit of Expertise for Complex Glomerular Diseases of Spain, Barcelona, Spain. Iacoboni G Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Carpio C, Sánchez-Salinas M, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. García-Carro C Nephrology Department, San Carlos Clinical University Hospital, Madrid, Spain. Alonso-Martínez C Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Clinical Kidney Journal;17(3); https://doi.org/10.1093/ckj/sfae027Test; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI21%2F01292; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/AC22%2F00029; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/RD21%2F0005%2F0016; León-Román J, Iacoboni G, Bermejo S, Carpio C, Bolufer M, García-Carro C, et al. Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies. Clin Kidney J. 2024 Mar;17(3):27.; https://hdl.handle.net/11351/11224Test

  5. 5
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Pérez Del Río E, Santos F, Veciana J Institute of Materials Science of Barcelona (ICMAB-CSIC), Bellaterra, Spain. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain. Román Alonso M, Rius I Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Castellote-Borrell M Institute of Materials Science of Barcelona (ICMAB-CSIC), Bellaterra, Spain. Dynamic Biomaterials for Cancer Immunotherapy, Max Planck Partner Group (ICMAB-CSIC), Bellaterra, Spain. Arribas J Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Cytotherapy;25(12); https://doi.org/10.1016/j.jcyt.2023.08.003Test; info:eu-repo/grantAgreement/EC/H2020/754397; Pérez del Río E, Román Alonso M, Rius I, Santos F, Castellote-Borrell M, Veciana J, et al. Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies. Cytotherapy. 2023 Dec;25(12):1293–9.; https://hdl.handle.net/11351/10658Test

  6. 6
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Rejeski K Department of Medicine III – Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany. Wang Y Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Albanyan O Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA. Munoz J Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA. Sesques P Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, Pierre-Bénite, France. Iacoboni G Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Department of Medicine, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: American Journal of Hematology;98(11); https://doi.org/10.1002/ajh.27056Test; Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, et al. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023 Nov;98(11):1699–710.; https://hdl.handle.net/11351/10464Test; 001051772500001

  7. 7
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Solano C Department of Hematology, Institute for Research (INCLIVA), Hospital Clínico Universitario, Valencia, Spain. School of Medicine, Department of Medicine, University of Valencia, Valencia, Spain. Castro-Rebollo P Medical Intensive Care Unit, Hospital Clinic de Barcelona, Barcelona, Spain. Pérez-Martínez A Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, Spain. López-Corral L Hematology Service, Hospital Clínico Universitario de Salamanca, Salamanca, Spain. Barba-Suñol P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Kwon M Hematology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: BMJ Open;13(7); http://dx.doi.org/10.1136/bmjopen-2022-071371Test; Solano C, Castro-Rebollo P, Pérez-Martínez A, López-Corral L, Barba-Suñol P, Kwon M, et al. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study. BMJ Open. 2023 Jul 25;13(7):e071371.; https://hdl.handle.net/11351/10150Test